补脾益肾复元汤联合司坦唑醇片治疗骨髓增生异常综合征难治性贫血60例临床观察

Clinical observation of Bupiyishenfuyuan decoction combined with stanozolol tablets on the treatment of patients with myelodysplastic syndrome-refractory anemia

目的观察补脾益肾复元汤联合司坦唑醇片治疗骨髓增生异常综合征难治性贫血(MDSRA)临床疗效。方法将120例MDS-RA患者随机分为2组。对照组60例采用单纯西药治疗,治疗组60例采用补脾益肾复元汤联合司坦唑醇片治疗。2组均3个月为1个疗程,治疗1个疗程后统计临床疗效,并观察治疗前后外周血象、T淋巴细胞亚群等指标的变化。结果治疗组总有效率83.3%,对照组总有效率55.0%,2组比较差异有统计学意义(P<0.05),治疗组疗效优于对照组;2组治疗后白细胞计数(WBC)、血红蛋白(Hb)及血小板计数(PLT)与本组治疗前比较均升高(P<0.05);2组治疗后WBC、Hb及PLT比较差异有统计学意义(P<0.05),治疗组WBC、Hb及PLT均高于对照组。2组治疗后CD4、CD4/CD8比值与本组治疗前比较升高(P<0.05),2组治疗后CD8较本组治疗前均下降(P<0.05);治疗组治疗后CD4、CD4/CD8比值均高于对照组治疗后(P<0.05),治疗组治疗后CD8均低于对照组治疗后(P<0.05)。结论补脾益肾复元汤联合司坦唑醇片治疗MDS-RA疗效确切,作用机制可能与调节机体免疫功能有关。

Objective To observe the therapeutic effect of Bupiyishenfuyuan decoction combined with stanozolol tablets on the treatment of patients with myelodysplastic syndrome - refractory anemia. Methods 120 pa- tients with myelodysplastic syndrome - refractory anemia were randomly divided into two groups. In the treatment group, Bupiyishenfuyuan decoction combined with stanozolol tablets was used ;while in the control group ,western med- icine therapy was selected. The therapeutic course was three months in two groups. The clinical efficacy, peripheral blood, T lymphocytes subsets were observed. Results Comparing the treatment effect between the two groups, the to- tal effective rate of the treatment group was 83.3% , while that of the control group was 55% ;there was significant difference in the two groups（P 〈 O. 05） ;After treatment,the level of WBC,Hb and PLT in the two groups increased compared with before treatment ,the difference was statistically significant（ P 〈 0.05 ） ;the level of WBC, Hb and PLT in the treatment group increased statistically significant compared with in the control group （ P 〈 0 05 ）. After treat- ment,the level of CD4, CD4/CD8 ratio increased, while the level of CD8 ＋ values declined, compared with before treatment, the difference was significant （ P 〈 O. 05 ）. The level of CD4, CD4/CD8 in the treatment group increased sta- tistically significant compared with in the control group （ P 〈 0 05 ）. While the level of CD8 values in the treatment group declined, compared with the control group, the difference was significant （ P 〈 0.05 ）. Conclusion The thera- peutic effect of Bupiyishenfuyuan decoction combined with stanozolol tablets on the treatment of patients with myelo- dysplastic syndrome - refractory anemia was definite, the mechanism may be related with the regulation of immune function.